ITGAM and neoplasm: IYIY-I2-BODIPY treated mice had significant lower level of G-MDSCs (CD11b+ Ly6G+) in spleen (4.9% ± 0.5%; p < 0.05) and tumor microenvironment (TM) (1.1% ± 0.3%; p < 0.05) at 2 h, at approximately 2-fold and 4-fold lower respectively compared to the other three control groups.